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Abstract
Up to 13% of women may experience symptoms of depression during pregnancy or in the postpartum period.
Depression during pregnancy has been associated with an increased risk of adverse neurodevelopmental outcomes in
the child and epigenetic mechanisms could be one of the biological pathways to explain this association. In 844
mother–child pairs from the Avon Longitudinal Study of Parents and Children, we carried out an epigenome-wide
association study (EWAS) to investigate associations between prospectively collected data on maternal depression
ascertained by the Edinburgh Postnatal Depression Scale in pregnancy and DNA methylation in the cord blood of
newborn offspring. In individual site analysis, we identiﬁed two CpG sites associated with maternal depression in the
middle part of pregnancy. In our regional analysis, we identiﬁed 39 differentially methylated regions (DMRs). Seven
DMRs were associated with depression at any time point during pregnancy, 7 associated with depression in mid-
pregnancy, 23 were associated with depression in late pregnancy, and 2 DMRs were associated with depression
throughout pregnancy. Several of these map to genes associated with psychiatric disease and brain development. We
attempted replication in The Generation R Study and could not replicate our results. Although our ﬁndings in ALSPAC
suggest that maternal depression could be associated with cord blood DNA methylation the results should be viewed
as preliminary and hypothesis generating until further replicated in a larger sample.
Introduction
Up to 13% of women experience symptoms of depres-
sion during pregnancy or postpartum1,2. Depression
during pregnancy has been associated with an increased
risk of adverse neurodevelopmental outcomes in the off-
spring3–5. Children of mothers with depression during
pregnancy have also been shown to be more likely to
develop a psychiatric disorder later in life6–8. The biolo-
gical mechanisms behind the association between
prenatal maternal depression and predisposition to later
behavioural problems, learning difﬁculties, and psychia-
tric illness in the offspring have been extensively dis-
cussed, and it has been hypothesised, that epigenetic
pathways could be one of the biological pathways
involved9. Epigenetics is the study of potentially heritable
molecular modiﬁcations to DNA and histone proteins
that can affect gene expression without change to the
underlying DNA sequence10. The most frequently studied
epigenetic phenomenon is DNA methylation where CpG
dinucleotides undergo a process of cytosine methylation
which can alter chromatin accessibility and thereby gene
transcription10.
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Timing of exposure to maternal depression may be
important in understanding the causal relationship.
Human studies suggest that the second and early third
trimesters are the more sensitive periods when exposures
to stressful life events increase the risk of offspring ill-
ness11, although the evidence is inconsistent12. Studies
investigating candidate genes (NR3C1 and SLC6A4) in
relation to maternal depression during pregnancy have
suggested trimester-speciﬁc differences in methylation
patterns in the cord blood of the offspring13,14.
The aim of this study was to test the hypothesis that
prenatal maternal depression would be associated with
epigenome-wide differences in methylation in the cord
blood of newborns in a large birth cohort study.
Methods
Participants
The Avon Longitudinal Study of Parents and Children
(ALSPAC) recruited 14,541 pregnant women resident in
Avon, UK with an expected delivery date falling between 1
April 1991 and 31 December 1992 (ref. 15). During
pregnancy the included women were sent up to four self-
completion postal questionnaires. At least one ques-
tionnaire was completed by 14,119 women and 11,545
women completed all four questionnaires16. These ques-
tionnaires included questions on lifestyle, mental health,
diet, medication use, education, occupation, ethnicity,
alcohol, and tobacco use. Two of the questionnaires
administered around the 18th and the 32nd week of
pregnancy contained questions concerning depression.
The study website contains details of all data that is
available through a fully searchable data dictionary17
(http://www.bristol.ac.uk/alspac/researchers/). Ethical
approval for the study was obtained from the ALSPAC
Ethics and Law Committee and the Local Research Ethics
Committees.
We included women with singleton pregnancies where
the woman had completed both questionnaires contain-
ing questions on depression during pregnancy and had a
child with cord blood DNA methylation data. ALSPAC
includes very few pregnancies of non-Caucasian ethnicity,
so we excluded those from the study (Fig. 1).
Measure of maternal depression
The postal questionnaires at 18 and 32 weeks of preg-
nancy included the 10-item Edinburgh Postnatal
Depression Score (EPDS)18. The EPDS is a validated
questionnaire to screen women for depression post-
partum as well as during pregnancy19. Scores of ≥12 have
a high correlation to clinically diagnosed depressive dis-
orders20. A total of 844 women had data on EPDS scores
and offspring cord blood DNA methylation (Fig. 1).
In our primary analysis we investigated whether
screening positive for depression (EPDS ≥ 12) at either
time point during pregnancy was associated with differ-
ential cord blood DNA methylation. Therefore, offspring
of women who had an EPDS ≥ 12 at either week 18 or
week 32 were considered exposed and these women will
be referred to as depressed throughout this paper. We did
three secondary analyses investigating the methylation
differences in children of mothers with depression in mid-
pregnancy only (EPDS ≥ 12 at week 18 and ≤12 at week
32), late in pregnancy only (EPDS ≥ 2 at week 32 and ≤12
at week 18), and at both time points in pregnancy
(EPDS ≥ 12 at both weeks 18 and 32). The reference was
offspring of women with EPDS < 12 at both week 18 and
week 32.
Methylation data
The procedure for collecting and storing cord blood
samples is described elsewhere21. The DNA methylation
analysis and the preprocessing of data were performed at
the University of Bristol as a part of the ARIES project22.
The ARIES project holds DNA methylation data on just
under 1000 cord blood samples. DNA methylation was
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Fig. 1 Flowchart illustrating the selection of participants from
ALSPAC
Viuff et al. Translational Psychiatry           (2018) 8:244 Page 2 of 10
measured in cord blood samples using the Illumina Inﬁ-
nium HumanMethylation 450K BeadChip assay23. This
platform analyses the methylation level of over 485,000
CpG sites in one array using bisulﬁte converted genomic
DNA. The level of methylation is reported as a beta-value
(β-value) ranging from 0 (completely unmethylated) to 1
(completely methylated).
Data were pre-processed in R (version 3.0.1) using the
WateRmelon package24 and functional normalisation was
performed using the Mefﬁl package in R25 as an attempt
to reduce non-biological differences between probes. We
removed 11,607 probes mapping to the Y or X chromo-
somes or because they were SNPs included on the array
for control purposes. In all, 2626 probes with a detection
p-value >0.05 were also removed. We identiﬁed extreme
outliers in the methylation data using the Tukey
method26. This method uses the interquartile range (IQR)
and extreme outliers are deﬁned as values outside ﬁrst
quartile−3×IQR and third quartile+3×IQR. These probes
were set as missing in the dataset.
Covariates
We adjusted for potential confounders, which we
selected with the help of Directed Acyclic Graphs
(DAGs)27. The potential confounders were maternal
education, parity, smoking, maternal pre-pregnancy BMI,
and maternal age at delivery. We also adjusted for esti-
mated cell proportions in the cord blood samples and
technical batch. Maternal education was deﬁned as having
achieved below A-levels or A-levels and above. Parity was
deﬁned as no children or ≥1 child. Smoking was deﬁned
as any smoking during pregnancy or no smoking during
pregnancy. Maternal age was included as a continuous
variable. Cell proportions were estimated using the
method developed by Houseman et al.28 and the cord
blood reference panel published by Bakulski et al.29. We
adjusted for technical batch using surrogate variable
analysis (SVA)30. Using the sva package in R we estimated
10 surrogate variables which are covariates constructed
from the data to adjust for unknown and un-modelled
factors associated with the technical batch. Those surro-
gate variables not associated with the trait of interest are
included as covariates in the regression analysis.
Statistical analysis
Single site regression analyses
Linear regression was applied to investigate the asso-
ciation between maternal depression and methylation
changes in the cord blood of the newborn. These EWASs
were conducted in R version 3.0.2.
In our main analysis, DNA methylation (untransformed
β-values) was the outcome. We ran four models to
interrogate associations between depression at any time
during pregnancy and DNA methylation: (1) adjusted for
batch; (2) adjusted for batch and estimated cell proportion
types; (3) adjusted for batch and covariates: maternal age,
maternal pre-pregnancy BMI, parity, smoking, and
maternal education; (4) adjusted for batch, covariates, and
cell proportion types.
In secondary analyses, we applied the same four models,
deﬁning our exposure as depression in mid-pregnancy
only, late pregnancy only, and depression at both time
points.
p-Values were adjusted for genome-wide signiﬁcance
using false discovery rate (FDR) adjustment and only sites
with FDR-corrected p-values <0.05 were considered sta-
tistically signiﬁcant.
Regional analyses
When multiple adjacent CpG sites are differentially
methylated, it is referred to as a differentially methylated
region (DMR)31. DMRs may be more biologically
important than differential methylation of individual,
isolated CpGs, and region-based approaches are statisti-
cally more powerful with a lower rate of false positive
ﬁndings compared to EWAS at individual CpGs. There-
fore, in addition to the single-site analyses, we also per-
formed regional analyses using Comb-P32. This method
combines adjacent p-values from the single CpG analysis,
corrects for correlation with neighbouring CpGs within
1000 bp applying the Stouffer-Liptak method, and adjusts
for multiple testing using a Sidak correction33.
For each exposure of interest (depression at any time,
mid-pregnancy, late pregnancy, and at both time points),
we performed regional analyses on the results of the
single-site analyses obtained using the fully adjusted
model (model 4).
Enrichment analysis
We used the missMethyl R package34 to perform gene
set enrichment analysis within the DMRs associated
with depression in each of the four exposures of interest.
This considers the differing number of sites associated
with each gene on the Illumina 450K array. We tested
for enrichment of any Gene Ontology (GO)35 classiﬁ-
cation term and Kyoto Encyclopaedia of Genes and
Genomes (KEGG) pathways36. p-Values were adjusted
for multiple testing using the FDR method. Only terms
with FDR-corrected p-values <0.05 were considered
signiﬁcant.
Replication
We used data from the Generation R Study37 based in
Rotterdam, the Netherlands for replication of our initial
observations in ALSPAC. The Generation R Study is a
population-based prospective cohort study from foetal life
onwards. It includes 9778 women and their children, born
between April 2002 and January 2006. The study has been
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approved by Medical Ethical Committee of Erasmus MC,
University Medical Center Rotterdam, and written con-
sent was obtained for all participants.
The Generation R Study Biobank has DNA methylation
results from 1339 cord blood samples measured using the
Illumina 450K Inﬁnium BeadChip38. The depression
subscale of the Brief Symptom Inventory (BSI)39 was
completed at 20 weeks of pregnancy. This timing corre-
sponds with the EPDS score from week 18 in ALSPAC.
The BSI is a 53-item version of the Symptom Checklist-90
(SCL-90) that measures emotional-behavioural function-
ing. Information about maternal education, parity, and
smoking during pregnancy was collected by self-reported
questionnaires during pregnancy. Maternal education was
classiﬁed in two levels: A-level or above (post-age 16 or
above) and below A-level (education level of age 16).
Parity was deﬁned as no children or ≥1 child, and smoking
during pregnancy as no smoking in pregnancy or any
smoking during pregnancy. Pre-pregnancy BMI was cal-
culated based on maternal pre-pregnancy weight,
obtained by self-reported questionnaires, and maternal
height measured at enrolment. Maternal age at delivery
was calculated based on the date of birth of the mother
and the child (Table S1).
A single-site regression analysis of the Generation R
study methylation data was performed as well as a
regional analysis as described above using the fully
adjusted model. Cell proportions were adjusted for using
the Houseman method with the reference panel for cord
blood published by Bakulski et al.29. Plate ID (n= 27) was
included in models as a covariate to adjust for technical
batch. We used these results to do a look up of the results
from our single site analysis and our DMR analysis in
ALSPAC.
Methylation quantative trait loci analysis
When performing EWAS studies it must be considered
that the methylation variation may partly be explained by
underlying genetic variation. DNA sequences that are
associated with patterns in DNA methylation are referred
to as methylation quantative trait loci (mQTLs)40. These
can act either in cis (within 1MB either side of the CpG
probe) or trans (further than 1MB from the CpG probe).
We looked up any maternal depression-associated CpG
sites in a database of mQTLs (http://www.mqtldb.org/)41
previously identiﬁed in the cord blood of 771 ALSPAC
children41. mQTLs were included in the database if the
association between the SNP and the CpG had a p-value
<1 × 10–7.
Results
We had complete data on exposure to maternal
depression during pregnancy and methylation changes in
the cord blood of the offspring in 844 mother–child pairs
in ALSPAC. Of these women 204 screened positive for
depression at any time point in pregnancy: 53 women
were depressed only in mid-pregnancy, 85 women only in
late pregnancy, and 66 women at both time points. Our
reference group consisted of 644 women classiﬁed as not
depressed at any point during pregnancy.
More women with depression reported smoking during
pregnancy than women in the reference group. Women in
the reference group had a higher level of education than
women with depression. The groups were comparable
regarding other characteristics (Table 1).
Single site regression analyses
In our main analysis (depression at any time point in
pregnancy), we found no signiﬁcantly differentially
Table 1 Characteristics of the included women
n= 844 Depression any time in
pregnancy (n= 204)
(EPDS ≥ 12)
Depression in mid-
pregnancya (n= 53)
Depression in late
pregnancyb (n= 85)
Depression throughout
pregnancyc (n= 66)
No depression in
pregnancy (n= 644)
(EPDS < 12)
Age (years)
(mean (95% CI))
29.4(28.7; 30) 29.4(28.1; 30.7) 29.7(28.6; 30.8) 28.8(27.6; 30.1) 29.7 (29.4; 30.1)
BMI (mean
((95% CI))
22.7(22.2; 23.2) 23.2(22.2; 24.2) 22.1(21.4; 22.8) 23.1(22; 24.2) 22.9(22.6; 23.2)
Parity (n)
No children 82 (41%) 23(44%) 29(35%) 30(45%) 314(49%)
≥1 child 116 (56%) 28(53%) 53(62%) 34(52%) 312(48%)
Smoking in pregnancy (n)
No smoking 150 (74%) 39 (74%) 68 (80%) 43 (65%) 584 (91%)
Any smoking 52 (25%) 14 (26%) 15 (18%) 23 (35%) 60 (9%)
Education Level
O-levels/GCSE 117 (57%) 26 (49%) 47 (55%) 44 (67%) 312 (49%)
A-levels and
above
85 (42%) 25 (47%) 38 (45%) 22 (33%) 331 (51%)
aEPDS ≥ 12 at 18 weeks only b EPDS ≥ 12 at 32 weeks only c EPDS ≥ 12 at 18 and 32 weeks
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methylated single CpG sites (FDR-corrected p-value
<0.05) in any of the four models.
When investigating depression in mid-pregnancy (up to
week 18), we identiﬁed two CpGs with FDR-corrected p-
values <0.05 (Fig.2). Methylation of cg08667740, located
on a CpG shore in the body of the CYBA gene, was 2.5%
(β=−0.025; p= 3.9 × 10−8) lower in the umbilical cord
blood of children exposed to maternal depression in mid-
pregnancy, relative to unexposed children. Methylation of
cg22868225, in the body of the PRKCZ gene, was 0.5%
lower (β=−0.005; p= 5.89 × 10−8). This association was
present in all four models. There were no CpGs with
FDR-corrected p-value <0.05 in the single-site EWAS of
depression in late pregnancy or depression throughout
pregnancy in any of the four models.
Regional analysis
In regional analyses we identiﬁed 39 differentially
methylated regions across all four depression exposures
using the fully adjusted model (Sidak-corrected p < 0.05).
Seven DMRs were associated with depression at any time
point during pregnancy, 7 associated with depression in
mid-pregnancy, 23 were associated with depression in late
pregnancy, and 2 DMRs were associated with depression
throughout pregnancy (Table 2).
Three DMRs (mapping to HFMI, CARTPT, and
RASIP1K) were common to two exposures: depression at
any time point during pregnancy and depression in late
pregnancy only. These two analyses also identiﬁed DMRs
in close proximity to each other, but not identical. These
DMRs both mapped to the HCG4P6 gene.
The regional analyses in women with depression at any
time point during pregnancy and depression throughout
pregnancy did not share mutual DMRs. They did however
identify neighbouring DMRs that both mapped to the
GNAS gene.
No mutual DMRs were identiﬁed in the analyses of the
cord blood from offspring having been exposed to
depression in mid-pregnancy, late, and throughout preg-
nancy, respectively.
Functional gene enrichment analysis (GO and KEGG
analyses)
Among the DMRs speciﬁc to depression throughout
pregnancy we found 1 KEGG pathway (related to insulin
secretion) but no enriched biological process GO terms
(FDR < 0.05).
Replication
Our look up of the results from the single site analysis
and the regional analysis in ALSPAC did not replicate in
the Generation R sample.
Of the two CpG sites (cg08667740 and cg22868225)
that were speciﬁc to mid-pregnancy maternal depression
in ALSPAC, one was associated with depression in Gen-
eration R with the same direction of effect. The other CpG
was associated with depression with the opposite direc-
tion of effect. None of them reached statistical sig-
niﬁcance (Table 3).
In the regional analysis we found no mutual DMRs in
the two datasets. Out of the 68 CpGs within the seven
DMRs speciﬁc to depression in mid-pregnancy in the
ALSPAC regional analysis, 49 (72%) showed the same
direction of association in the Generation R study, but
none survived correction for multiple testing (Tables S2,
S3).
Methylation quantative trait loci analysis
Of the two CpGs identiﬁed in our single site analysis,
cg22868225 was associated with two trans-SNPs located
on chromosome 10 (rs17569335, β= 0.267, p= 7.8e-08
and rs2768469, β= 0.276, p= 3.41e-08), and cg08667740
was associated with one trans-acting SNP (rs13190610, β
=−1.352, p= 2.04e-08) located on chromosome 5.
Neither CpG was associated with any cis-acting SNPs,
suggesting that the observed methylation differences
between offspring of depressed and unaffected mothers is
not being driven by the underlying genetic architecture.
Discussion
Maternal depression (occurring at any time point dur-
ing pregnancy) was associated with offspring cord blood
Fig. 2 Volcano plot illustrating the two signiﬁcant single CpG
sites from the linear regression analysis speciﬁc to depression in
mid-pregnancy
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Table 2 Results of the regional analysis
Exposure group Gene Location No. of CpGs DMR Median beta (range) Sidak-corrected p-values
Any time point RASIP1 19q13.33 5 Chr19:49223814–49224166 0.02 (0.01; 0.02) 2.8e-05
HFM1 1p22.2 6 Chr1:91852791–91853090 −0.01 (−0.02; 0.0) 6.8e-04
NNAT 20q11.23 23 Chr20:36148604–36149082 −0.01 (−0.02; 0.00) 7.1e-04
HCG4P6 6p22.1 8 Chr6:29893926–29894163 0.04 (0.0; 0.07) 2.1e-03
GNAS 20q13.32 9 3Chr20:57427556–57427831 0.01 (0.0; 0.02) 8.0e-03
CARTPT 5q13.2 6 Chr5:71146767–71146877 −0.02 (−0.02; −0.00) 2.8e-02
ARL5C 17q12 3 Chr17:37322028–37322432 0.02 (0.01; 0.04) 5.3e-04
Mid-pregnancy depression HOXA5 7p15.2 42 Chr7:27183133–27184522 −0.02 (−0.06; 0.00) 8.4e-10
LYNX1 8q24.3 7 Chr8:143859669–143859991 0.03 (0.02; 0.06) 1.2e-05
SULF1 8q13.2 8 Chr8:70378380–70378995 0.01 (0.00; 0.02) 8.0e-05
C6orf227 6p21.31 8 Chr6:33561099–33561450 0.01 (0.00; 0.03) 1.5e-04
RGS1 1q31.2 2 Chr1:192544716–192544903 0.04 (0.01; 0.07) 3.2e-03
BCL11B 14q32.2 3 Chr14:99655593–99655748 −0.04 (−0.06; −0.03) 9.2e-03
SNED1 2q37.3 2 Chr2:242031617–242031695 0.01 (−0.00; 0.02) 3.0e-02
Late depression CARTPT 5q13.2 6 Chr5:71146767–71146877 −0.03 (−0.04; −0.02) 6.6e-08
HFM1 1p22.2 6 Chr1:91852791–91853090 −0.02 (−0.03; −0.00) 1.7e-06
HCG4P6 6p22.1 16 Chr6:29893926–29894342 0.02 (0.00; 0.01) 1.8e-05
PLEKHG1 6q25.1 3 Chr6:151125848–151125886 0.03 (0.03; 0.03) 3.0e-05
FAM20C 7p22.3 5 Chr7:213469–213849 −0.02 (−0.04; 0.00) 1.0e-04
DDO 6q21 4 Chr6:110720918–110721350 0.05 (0.03; 0.06) 1.3e-04
RASIP1 19q13.33 5 Chr19:49223814–49224166 0.02 (0.01; 0.03) 1.7e-04
HLA-DRB6 6p21.32 14 Chr6:32551749–32552247 −0.05 (−0.10; −0.00) 2.5e-04
JA668105 2q21.2 3 Chr2:133025652–133025918 −0.01 (−0.03; 0.03) 5.3e-04
TRNA_Ala 6p22.1 17 Chr6:28583971–28584289 −0.01 (−0.03; −0.00) 6.1e-04
KLHL30 2q317.3 6 Chr2:239047029–239047337 0.02 (0.01; 0.04) 1.1e-03
MUC4 3q29 7 Chr3:195489708–195490170 0.05 (0.02; 0.07) 1.1e-03
JPH3 16q24.2 2 Chr16:87682036–87682143 −0.08 (−0.01; −0.05) 3.5e-03
PSPH 7p11.2 3 Chr7:56242181–56242555 0.04 (0.03; 0.04) 5.5e-03
AK054726 1q42.2 5 Chr1:234367145–234367587 −0.03 (−0.04; −0.03) 6.4e-03
LMO7 13q22.2 4 Chr13:76334583–76334867 0.02 (0.02; 0.02) 6.7e-03
ESRRG 1q41 3 Chr1:217306590–217306764 −0.04 (−0.04; −0.03) 9.0e-03
SDK1 7p22.2 3 Chr7:4244250–4244644 −0.06 (−0.01; −0.05) 1.0e-02
SLCO5A1 8q13.3 4 Chr8:70602451–70602610 −0.01 (−0.03; 0.00) 2.0e-02
IFITM4P 6p22.1 4 Chr6:29723301–29723408 −0.04 (−0.06; −0.04) 2.9e-02
DLG2 11q14.1 3 Chr11:85195094–85195206 −0.01 (−0.02; −0.01) 3.1e-02
BIN1 2q14.3 2 Chr2:127811805–127811854 −0.03 (−0.04; −0.03) 3.2e-02
DLX1 2q31.1 2 Chr2:172948725–172948826 0.01 (0.01; 0.01) 4.8e-02
All GNAS 20q13.32 17 Chr20:57427472–57428033 0.02 (0.00; 0.03) 4.1e-09
TRPM4 19q13.33 4 Chr19:49713645–49714045 −0.03 (−0.05; −0.02) 1.1e-03
The italics boxes indicate DMRs that are common to more than one exposure
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DNA methylation at seven DMRs, but no individual CpG
sites in our main analysis in ALSPAC.
Depression in mid-pregnancy, late pregnancy, and at
both time points (throughout pregnancy) was associated
with 7, 23, and 2 DMRs, respectively. Depression in mid-
pregnancy was the only exposure deﬁnition associated
with any individual CpG sites with genome-wide sig-
niﬁcance. However, ﬁndings for the two identiﬁed CpGs
(cg08667740 and cg22868225) did not replicate in Gen-
eration R. Although we found that 72% CpG sites within
DMRs identiﬁed in ALSPAC showed the same direction
of association between antenatal maternal depression and
offspring DNA methylation in Generation R, none of our
ﬁndings replicated with statistical signiﬁcance.
Although none of the ALSPAC DMRs replicated in the
Generation R study with statistical signiﬁcance, the
direction of association was the same at some regions that
have previously been associated with neurodevelopmental
and psychiatric outcomes. Out of the 49 CpG sites that
had the same direction of association in both ALSPAC
and the Generation R study 35 were hypomethylated in
both cohorts and located in the promoter region of the
HOXA5 gene. This gene has been associated with
depression in early pregnancy and this gene family is
known to have important roles in embryonic develop-
ment42 and has been seen to be downregulated in the
prefrontal cortex of depressed suicide subjects43.
Another seven CpG sites that were all hypermethylated
in both ALSPAC and the Generation R study mapped to
the promoter region of the LYNX1 gene. This gene was
previously found to be hypermethylated in the hippo-
campus from patients with major depressive disorders44.
In this study they conducted both a genome-wide asso-
ciation study using the 450K array and investigated the
LYNX1 gene using bisulﬁte pyrosequencing. Both meth-
ods yielded the same result.
In the cord blood of the children exposed to depression
at any time point in pregnancy we found a DMR spanning
more than 20 CpG sites mapping to the promotor region
of the NNAT gene which is an imprinted gene that may be
involved in brain development and in forming and
maintaining the structure of the nervous system45.
The NNAT gene has been investigated previously in
relation to maternal depression during pregnancy46,47.
These studies investigated imprinted genes but none of
them found any association between depression during
pregnancy and changes in DNA methylation in cord
blood of newborn infants in this gene.
In candidate gene studies, Devlin et al.13 and Ober-
lander et al.14 found associations between maternal
depressed mood during pregnancy and variation in cord
blood DNA methylation at the SLC6A4 and NR3C1 genes,
respectively. These ﬁndings were not replicated in our
study.
There has been one previous EWAS of maternal
depressed mood or anxiety during pregnancy and cord
blood methylation in just 13 children48. Of the 10 CpG
sites differentially methylated with FDR < 0.05 in this
study, 5 CpG sites were associated with depression in the
same direction in our study, but the smallest FDR-
corrected p-value for these associations was 0.999 (Table
S4).
Strengths and limitations
The ALSPAC study is a large birth cohort with very
comprehensive, prospectively collected data on a popu-
lation level reducing the possibility of recall bias or reverse
causality.
Another strength to this study is the use of the EPDS,
which is a self-reported screening tool for depression that
correlates with clinical depression with a high sensitivity
at the chosen cut off of 12 points19. However, it should be
noted that this is a screening tool and therefore the pre-
valence of depression (20%) in our study was higher than
estimates for clinical diagnoses (~13%)1. It is interesting
that we ﬁnd at least some association between depression
and offspring methylation in our study, given that women
in our study are likely to have with milder forms of
depression. In future studies it would be interesting to
investigate the association between exposure to clinically
veriﬁed depression and changes in DNA methylation in
cord blood from the exposed infants.
A limitation to this study is the coverage of the 450K
BeadChip. It covers less than 2% of the CpG sites in the
human epigenome. This limited coverage could result in
an underestimation of the true methylation differences in
epigenomic areas not covered by this array, including
methylation variable loci that have previously been
implicated in depression.
Even though, to our knowledge, this study is the largest
on depression during pregnancy and cord blood methy-
lation, inability to detect true associations in our discovery
(ALSPAC) and replication (The Generation R Study)
cohorts due to lack of statistical power is entirely possible.
Furthermore, the Generation R Study used a different
measure of depression to the ALSPAC cohort. The
Table 3 Table of replication in Generation R of the
signiﬁcant single CpG sites found in ALSPAC
Probe ID ALSPAC mid-pregnancy
depression
Generation R Study
Beta SE p-value Beta SE p-value
cg08667740 −0.025 0.005 3.90E-08 0.003 0.002 0.186
cg22868225 −0.005 0.001 5.89E-08 −0.001 0.001 0.672
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correlation between the two different mood scores used
by ALSPAC (EPDS) and The Generation R Study (BSI)
has been studied sparsely49 and the relatively low may
correlation contribute to the lack of replication. Using two
different instruments may however be considered a
strength in this study. The convergent direction of asso-
ciations between the cohorts point towards an effect of
depression rather than an instrument speciﬁc effect.
The methylation data used in this study are derived
from cord blood, and it could be argued that it would be
more appropriate to study the association of maternal
depression and DNA methylation in a more biologically
relevant tissue, for example, infant brain tissue. However,
aside from the obvious ethical and feasibility issues, there
is increasing evidence to suggest that peripheral tissues
may have some utility in epigenetic epidemiological stu-
dies of brain disorders50,51.
The composition of cells in umbilical cord blood may
confound results if the composition is related to exposure
or outcome. In this study, it is plausible that maternal
depression, or exposures related to depression, such as
smoking, could inﬂuence cell composition in cord blood.
In order to limit the effect of this we adjusted for cord
blood cell composition using the Andrews and Bakulski
cord blood reference panel. We also investigated the
association between exposure and estimated cell propor-
tion. Maternal depression was not associated with the
estimated cell proportions (Table S5).
We aknowledge, that it could be a limitation to this
study, that we have not conﬁrmed the signiﬁcant CpG
sites by more quantitative analyses, e.g. pyrosequencing.
The 450K array is however well validated, and yields
values consistent with pyrosequencing52.
We have chosen the included covariates using the the-
ory of DAGs and have therefore not included covariates
often included in previous studies such as, e.g. child-sex
and gestational age that are not true confounders with
direct effect on both exposure and outcome. Conditioning
on such covariates could confound the results and either
over- or underestimate the true association depending on
the source of bias53,54.
The possibility of residual confounding cannot be ruled
out but the sample size was not sufﬁcient for the addition
of more variables to the analysis.
However, despite this, to our knowledge, being the
largest study of maternal depression and cord blood
methylation to date, the sample size was not sufﬁcient to
allow for more stratiﬁed analyses or the addition of more
variables to the multivariable analyses.
More smokers were found among depressed women
compared to controls. Thus, residual confounding by
smoking may exist. However, we found no overlap
between the top CpG sites found in our analyses of
depressed women vs. controls and the smoking-associated
CpG sites from a previous study55. This suggests that
smoking may not be a strong confounder in our study.
Finally, the effect sizes in this study are rather small.
The biological signiﬁcance of this is unclear, and could
not be explored further due to the lack of data such as
downstream gene expression. Other environmental epi-
genetic studies do show that often only small-magnitude
effects results from these exposures56, and future studies
should evaluate the signiﬁcance of these.
Conclusion
We identiﬁed some single and regional DNA methyla-
tion differences in umbilical cord blood of newborns
exposed to maternal depression during pregnancy, com-
pared to newborns that were unexposed but these results
did not replicate in an independent cohort. Further stu-
dies with larger sample sizes and better epigenomic cov-
erage investigating more tissue types are needed to further
investigate whether epigenetics could be part of a biolo-
gical pathway linking maternal depression during preg-
nancy to childhood outcomes.
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